Mercer Global Advisors Inc. ADV Boosts Stock Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Mercer Global Advisors Inc. ADV grew its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 12.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 174,550 shares of the company’s stock after acquiring an additional 18,819 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in Hims & Hers Health were worth $4,221,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Means Investment CO. Inc. boosted its stake in Hims & Hers Health by 23.5% during the 4th quarter. Means Investment CO. Inc. now owns 50,040 shares of the company’s stock valued at $1,210,000 after acquiring an additional 9,508 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Hims & Hers Health during the fourth quarter worth about $18,048,000. State of Alaska Department of Revenue acquired a new position in Hims & Hers Health in the fourth quarter worth about $2,628,000. Pacer Advisors Inc. acquired a new stake in Hims & Hers Health during the fourth quarter valued at approximately $374,000. Finally, Genesee Capital Advisors LLC bought a new position in Hims & Hers Health during the 4th quarter worth approximately $889,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Stock Up 2.7 %

Shares of HIMS opened at $41.94 on Tuesday. The firm has a market capitalization of $9.32 billion, a PE ratio of 95.32 and a beta of 1.84. The firm has a 50-day moving average price of $32.22 and a 200 day moving average price of $31.70. Hims & Hers Health, Inc. has a 52-week low of $11.45 and a 52-week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $586.01 million during the quarter, compared to analysts’ expectations of $535.21 million. During the same period last year, the firm posted $0.05 earnings per share. The business’s revenue was up 110.7% on a year-over-year basis. On average, equities analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on HIMS. TD Cowen cut Hims & Hers Health from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $44.00 to $30.00 in a research note on Tuesday, April 29th. Bank of America upped their target price on Hims & Hers Health from $22.00 to $26.00 and gave the company an “underperform” rating in a report on Tuesday, April 29th. BTIG Research began coverage on Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target on the stock. Leerink Partners upped their price objective on Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a research note on Tuesday, February 25th. Finally, Piper Sandler raised their target price on Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday, February 25th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and a consensus target price of $36.92.

Insider Activity

In other Hims & Hers Health news, CEO Andrew Dudum sold 128,127 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total value of $7,465,960.29. Following the transaction, the chief executive officer now directly owns 97,687 shares of the company’s stock, valued at $5,692,221.49. This represents a 56.74 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $43.01, for a total value of $498,098.81. Following the sale, the chief financial officer now owns 107,789 shares of the company’s stock, valued at approximately $4,636,004.89. This represents a 9.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 650,500 shares of company stock worth $25,790,311. 17.71% of the stock is owned by company insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.